All About Drugs

Tout sur les médicaments הכל על תרופות كل شيئ عن الأدوية Все о наркотиках 关于药品的一切 డ్రగ్స్ గురించి అన్ని 마약에 관한 모든 것 Όλα για τα Ναρκωτικά Complete Tracking of Drugs Across the World by Dr Anthony Melvin Crasto, Worldpeacepeaker, worlddrugtracker, PH.D (ICT), MUMBAI, INDIA, Worlddrugtracker, Helping millions, 9 million hits on google on all websites, 2.5 lakh connections on all networks, “ALL FOR DRUGS” CATERS TO EDUCATION GLOBALLY, No commercial exploits are done or advertisements added by me. This is a compilation for educational purposes only. P.S. : The views expressed are my personal and in no-way suggest the views of the professional body or the company that I represent

Isis Pharmaceuticals, Inc.announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago

drugs Comments Off

Jun 042013

Isis Pharmaceuticals, Inc. (NASDAQ: ISIS) announced that data from the Phase 1 study of ISIS-STAT3Rx in patients with cancer were presented today at the American Society of Clinical Oncology in Chicago. Results of the initial dose escalation study in patients with metastatic cancer showed that ISIS-STAT3Rx treatment resulted in partial responses that were durable and prolonged in two out of three patients with diffuse large B-cell lymphoma (DLBCL) who were refractory to prior chemotherapy treatments. Isis and AstraZeneca are currently evaluating ISIS-STAT3Rx, in two clinical studies in patients with advanced lymphoma and metastatic liver cancer.

Selumetinib is the first drug ever to show significant benefit for patients with advanced uveal melanoma

Uncategorized Comments Off

Jun 042013

Two Array Invented MEK Inhibitors Showcased At ASCO
Sacramento Bee
AstraZeneca began a pivotal trial with selumetinib (an Array-invented drug) in thyroid cancer in May 2013 and expects to begin a Phase 3 trial in non-small cell lung cancer during the second half of 2013.

http://www.sacbee.com/2013/06/03/5466446/two-array-invented-mek-inhibitors.html

Two Array BioPharma-invented MEK inhibitors, selumetinib and MEK162, were showcased at the 49th annual meeting of the American Society of Clinical Oncology (ASCO).

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Experimental Drug Shows Benefits Against Melanoma in Early Study, Lambrolizumab activates body’s immune system to kill cancerous cells, researchers say

Uncategorized Comments Off

Jun 032013

Experimental Drug Shows Benefits Against Melanoma in Early Study
U.S. News & World Report
SUNDAY, June 2 (HealthDay News) — A new drug called lambrolizumab appears to improve outcomes in patients with advanced melanoma, according to the results of a phase 1 trial. Lambrolizumab is an antibody that works by revealing the cancer to the immune system so it can mount a response and kill the cancer cells with few serious side effects, the researchers said.

read all at

http://health.usnews.com/health-news/news/articles/2013/06/02/experimental-drug-shows-benefits-against-melanoma-in-early-study

by WORLD DRUG TRACKER

DR ANTHONY CRASTO

Immune-Based Drug Shows Promise Against Advanced Melanoma

Uncategorized Comments Off

Jun 022013

READ ALL AT

http://www.drugs.com/news/immune-based-shows-promise-against-advanced-melanoma-44809.html

PROCESS FOR MANUFACTURE OF TELMISARTAN PATENT US2013137878 (A1)30 MAY 2013

PATENTS Comments Off

Jun 012013

READ ALL AT

http://newdrugapprovals.wordpress.com/2013/06/01/process-for-manufacture-of-telmisartan-patent-us2013137878-a130-may-2013/

GSK, Genmab announce positive results from Phase III study of Arzerra (ofatumumab)

drugs Comments Off

Jun 012013

may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.

Discovery of Unexpectedly Active Group-Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

Uncategorized Comments Off

May 312013

Introduction of a sulfoximine group into anticancer candidates shows that sometimes sticking to the unconventional pays off

A Drug Discovery Detective Story-Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

Uncategorized Comments Off

May 312013

Biological activity of small-molecule RNA polymerase (RNAP) inhibitors revealed to come from polymeric impurity

Meat, Bacteria, and Atherosclerosis-By metabolizing L-carnitine, a nutrient abundant in red meat, intestinal bacteria promote atherosclerosis

Uncategorized 1 Response »

May 312013

By metabolizing L-carnitine, a nutrient abundant in red meat, intestinal bacteria promote atherosclerosis

Chinese HFMD vaccine impresses in Phase III

Uncategorized Comments Off

May 312013

read all at

http://www.fiercevaccines.com/story/chinese-hfmd-vaccine-impresses-phase-iii/2013-05-29

Older Entries Newer Entries

Categories

DR ANTHONY MELVIN CRASTO Ph.D amcrasto@gmail.com

MOBILE-+91 9323115463

GLENMARK SCIENTIST , NAVIMUMBAI, INDIA

……………………………………. DR ANTHONY MELVIN CRASTO Ph.D , Born in Mumbai in 1964 and graduated from Mumbai University, Completed his PhD from ICT ,1991, Mumbai, India in Organic chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARKPHARMA LTD, Research centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Prior to joining Glenmark, he worked with major multinationals like Hoechst Marion Roussel, now Sanofi Aventis, & Searle India ltd, now Rpg lifesciences, etc. He has worked in Basic research, Neutraceuticals, Natural products, Flavors, Fragrances, Pheromones, Vet Drugs, Drugs, formulation, GMP etc. He has total 25 yrs exp in this field, he is now helping millions, has 9 million hits on google on all organic chemistry websites. His New Drug Approvals , Green Chemistry International, Eurekamoments in Organic Chemistry , Organic Chemistry by Dr Anthony, WIX BLOG , are some most read chemistry blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 29 year tenure, good knowledge of IPM, GMP, Regulatory aspects, he has several international drug patents published worldwide . He has good proficiency in Technology Transfer, Spectroscopy , Stereochemistry , Synthesis, Reactions in Org Chem , Polymorphism, Pharmaceuticals , Medicinal chemistry , Organic chemistry literature , Patent related site , Green chemistry , Reagents , R & D , Molecules , Heterocyclic chem , Sourcing etc He suffered a paralytic stroke in dec 2007 and is bound to a wheelchair, this seems to have injected feul in him to help chemists around the world, he is more active than before and is pushing boundaries, he has 2.5 lakh connections on all networking sites, He makes himself available to all, contact him on +91 9323115463, amcrasto@gmail.com